// App-Quantinova.ai

1026 : Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Phallcon Study

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Giovanni Martinelli

  • Marco Vignetti

  • Hagop M. Kantarjian

  • David Gomez-Almaguer

  • Yosuke Minami

  • Herv Dombret

  • Bingxia Wang

  • E. Jane Leonard

  • Shouryadeep Srivastava

  • Josep-Maria Ribera

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • GIMEMA Research Foundation, Rome, Italy

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Hospital Universitario de Nuevo Leon, Monterrey, Mexico

  • National Cancer Center, EPOC, Chiba, Japan

  • Institut de Recherche Saint-Louis, Université de Paris,Paris,France

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Josep Carreras Research Institute,Badalona,Spain

Locations

  • United States

  • Italy

  • Mexico

  • Japan

  • France

  • Spain

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Prednisone

  • Ponatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT03589326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved